KRT18P47

Across TCGA pan-cancer cohorts, KRT18P47 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of KRT18P47’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where KRT18P47 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P47 is over-expressed in tumor.

LUAD, STAD, and PRAD are the cancer types where KRT18P47 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P47 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.033	.004	4	view →
STAD	All	All	+0.065	.017	2	view →
PRAD	All	All	+0.043	.019	2	view →
BRCA	All	III,IV	+0.034	.002	2	view →
COAD	Female	II,III,IV	+0.076	.042	1	view →
BLCA	All	IV	+0.068	.035	1	view →
LIHC	Female	II,III,IV	+0.025	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

KRT18P47–LUAD

Open the LUAD breakdown →